JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

TransMedics Group Inc

Chiusa

SettoreSettore sanitario

130.6 2.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

128.42

Massimo

134.02

Metriche Chiave

By Trading Economics

Entrata

9.2M

35M

Vendite

14M

157M

P/E

Media del settore

59.064

37.461

Margine di Profitto

22.181

Dipendenti

728

EBITDA

10M

46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+12.09% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

527M

4.1B

Apertura precedente

128.5

Chiusura precedente

130.6

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

TransMedics Group Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2025, 19:15 UTC

I principali Market Mover

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Confronto tra pari

Modifica del prezzo

TransMedics Group Inc Previsione

Obiettivo di Prezzo

By TipRanks

12.09% in crescita

Previsioni per 12 mesi

Media 144.5 USD  12.09%

Alto 170 USD

Basso 115 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TransMedics Group Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

9

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

92.43 / 94.18Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat